{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:00:18Z","timestamp":1793520018870,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T00:00:00Z","timestamp":1467417600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1007\/s00415-016-8219-8","type":"journal-article","created":{"date-parts":[[2016,7,2]],"date-time":"2016-07-02T02:32:58Z","timestamp":1467426778000},"page":"621-630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":219,"title":["Survival and long-term outcomes in late-onset Pompe disease following alglucosidase alfa treatment: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"264","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2757-8131","authenticated-orcid":false,"given":"Benedikt","family":"Schoser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Stewart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Kanters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alaa","family":"Hamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Jansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Karamouzian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,7,2]]},"reference":[{"issue":"6","key":"8219_CR1","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.ejhg.5200367","volume":"7","author":"MG Ausems","year":"1999","unstructured":"Ausems MG, Verbiest J, Hermans MP et al (1999) Frequency of glycogen storage disease type II in The Netherlands: implications for diagnosis and genetic counselling. Eur J Hum Genet 7(6):713\u2013716","journal-title":"Eur J Hum Genet"},{"key":"8219_CR2","first-page":"3389","volume-title":"The metabolic and molecular bases of inherited disease","author":"R Hirschhorn","year":"2001","unstructured":"Hirschhorn R, Reuser A (2001) Glycogen storage disease Type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver C, Beaudet A, Sly W, Valle D (eds) The metabolic and molecular bases of inherited disease, 8th edn. McGraw-Hill, New York, pp 3389\u20133420","edition":"8"},{"key":"8219_CR3","volume-title":"Clinical genetics in nursing practice","author":"FR Lashley","year":"2005","unstructured":"Lashley FR (2005) Clinical genetics in nursing practice, 3rd edn. Springer Publishing Company Inc., New York","edition":"3"},{"issue":"3","key":"8219_CR4","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.281.3.249","volume":"281","author":"PJ Meikle","year":"1999","unstructured":"Meikle PJ, Hopwood JJ, Clague AE, Carey WF (1999) Prevalence of lysosomal storage disorders. JAMA 281(3):249\u2013254","journal-title":"JAMA"},{"issue":"12","key":"8219_CR5","doi-asserted-by":"crossref","first-page":"2139","DOI":"10.1212\/01.WNL.0000165979.46537.56","volume":"64","author":"ML Hagemans","year":"2005","unstructured":"Hagemans ML, Winkel LP, Hop WC, Reuser AJ, Van Doorn PA, Van der Ploeg AT (2005) Disease severity in children and adults with Pompe disease related to age and disease duration. Neurology 64(12):2139\u20132141","journal-title":"Neurology"},{"issue":"3","key":"8219_CR6","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/mus.22329","volume":"45","author":"EJ Cupler","year":"2012","unstructured":"Cupler EJ, Berger KI, Leshner RT et al (2012) Consensus treatment recommendations for late onsent Pompe disease. Muscle Nerve 45(3):319\u2013333","journal-title":"Muscle Nerve"},{"issue":"15","key":"8219_CR7","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT Ploeg van der","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med 362(15):1396\u20131406","journal-title":"N Engl J Med"},{"issue":"3","key":"8219_CR8","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ymgme.2012.09.015","volume":"107","author":"AT Ploeg van der","year":"2012","unstructured":"van der Ploeg AT, Barohn R, Carlson L et al (2012) Open-label extension study following the late-onset treatment study (LOTS) of alglucosidase alfa. Mol Genet Metab 107(3):456\u2013461","journal-title":"Mol Genet Metab"},{"issue":"4","key":"8219_CR9","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","volume":"38","author":"JH Wokke","year":"2008","unstructured":"Wokke JH, Escolar DM, Pestronk A et al (2008) Clinical features of late-onset pompe disease: a prospective cohort study. Muscle Nerve 38(4):1236\u20131245","journal-title":"Muscle Nerve"},{"issue":"4","key":"8219_CR10","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00415-012-6636-x","volume":"260","author":"A Toscano","year":"2013","unstructured":"Toscano A, Schoser B (2013) Enzyme replacement therapy in late-onset Pompe disease: a systematic literature review. J Neurol 260(4):951\u2013959","journal-title":"J Neurol"},{"key":"8219_CR11","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","volume":"37","author":"L Anderson","year":"2014","unstructured":"Anderson L, Henley W, Wyat K et al (2014) Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 37:945\u2013952","journal-title":"J Inherit Metab Dis"},{"issue":"Suppl 16","key":"8219_CR12","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1183\/09041950.005s1693","volume":"6","author":"P Quanjer","year":"1993","unstructured":"Quanjer P, Tammeling G, Cotes J, Pedersen O, Peslin R, Yernault J (1993) Lung volumes and forced ventilatory flows. Eur Respir J 6(Suppl 16):5\u201340","journal-title":"Eur Respir J"},{"issue":"5","key":"8219_CR13","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1177\/0272989X13485157","volume":"33","author":"S Dias","year":"2013","unstructured":"Dias S, Sutton AJ, Welton NJ, Ades AE (2013) Evidence synthesis for decision making 3: heterogeneity\u2013subgroups, meta-regression, bias, and bias-adjustment. Med Decis Making 33(5):618\u2013640","journal-title":"Med Decis Making"},{"issue":"4","key":"8219_CR14","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1023\/A:1018598421607","volume":"7","author":"AP Dempster","year":"1997","unstructured":"Dempster AP (1997) The direct use of likelihood for significance testing. Statist Comput 7(4):247\u2013252","journal-title":"Statist Comput"},{"key":"8219_CR15","volume-title":"Bayesian approaches to clinical trials and health-care evaluation","author":"DJ Spiegelhalter","year":"2004","unstructured":"Spiegelhalter DJ, Abrams KR, Myles JP (2004) Bayesian approaches to clinical trials and health-care evaluation. Wiley, Chichester"},{"key":"8219_CR16","doi-asserted-by":"crossref","unstructured":"Gungor D, Kruijshaar M, Plug I et al. (2013) Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study. Orphanet J Rare Dis 8:49","DOI":"10.1186\/1750-1172-8-49"},{"key":"8219_CR17","doi-asserted-by":"crossref","unstructured":"Van Der Beek NA, De Vries JM, Hagemans ML et al. (2012) Clinical features and predictors for disease natural progression in adults with Pompe disease: a nationwide prospective observational study. Orphanet J Rare Dis 7:88","DOI":"10.1186\/1750-1172-7-88"},{"issue":"2","key":"8219_CR18","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","volume":"19","author":"NA Beek Van der","year":"2009","unstructured":"Van der Beek NA, Hagemans ML, Reuser AJ et al (2009) Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease. Neuromuscul Disord 19(2):113\u2013117","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"8219_CR19","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ymgme.2014.02.015","volume":"112","author":"C Andreassen","year":"2014","unstructured":"Andreassen C, Schlutter J, Vissing J, Andersen H (2014) Effect of enzyme replacement therapy on isokinetic strength for all major muscle groups in four patients with Pompe disease-a long-term follow-up. Mol Genet Metab 112(1):40\u201343","journal-title":"Mol Genet Metab"},{"issue":"6","key":"8219_CR20","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mus.23340","volume":"45","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S et al (2012) New motor outcome function measures in evaluation of Late-Onset Pompe disease before and after enzyme replacement therapy. Muscle Nerve 45(6):831\u2013834","journal-title":"Muscle Nerve"},{"issue":"6","key":"8219_CR21","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","volume":"33","author":"B Bembi","year":"2010","unstructured":"Bembi B, Pisa FE, Confalonieri M et al (2010) Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II. J Inherit Metab Dis 33(6):727\u2013735","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"8219_CR22","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.nmd.2011.04.001","volume":"21","author":"D Orlikowski","year":"2011","unstructured":"Orlikowski D, Pellegrini N, Prigent H et al (2011) Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease. Neuromuscul Disord 21(7):477\u2013482","journal-title":"Neuromuscul Disord"},{"key":"8219_CR23","doi-asserted-by":"crossref","unstructured":"De Vries JM, Van Der Beek NA, Hop WC et al. (2012) Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. Orphanet J Rare Dis 7:73","DOI":"10.1186\/1750-1172-7-73"},{"issue":"2","key":"8219_CR24","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10545-011-9393-6","volume":"35","author":"Y Furusawa","year":"2012","unstructured":"Furusawa Y, Mori-Yoshimura M, Yamamoto T et al (2012) Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study. J Inherit Metab Dis 35(2):301\u2013310","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"8219_CR25","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1468-1331.2008.02377.x","volume":"16","author":"T Merk","year":"2009","unstructured":"Merk T, Wibmer T, Schumann C, Kruger S (2009) Glycogen storage disease type II (Pompe disease)\u2014influence of enzyme replacement therapy in adults. Eur J Neurol 16(2):274\u2013277","journal-title":"Eur J Neurol"},{"issue":"4","key":"8219_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.clineuro.2010.12.005","volume":"113","author":"GK Papadimas","year":"2011","unstructured":"Papadimas GK, Spengos K, Konstantinopoulou A et al (2011) Adult Pompe disease: clinical manifestations and outcome of the first Greek patients receiving enzyme replacement therapy. Clin Neurol Neurosurg 113(4):303\u2013307","journal-title":"Clin Neurol Neurosurg"},{"issue":"3","key":"8219_CR27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.ymgme.2012.04.027","volume":"106","author":"TT Patel","year":"2012","unstructured":"Patel TT, Banugaria SG, Case LE, Wenninger S, Schoser B, Kishnani PS (2012) The impact of antibodies in late-onset Pompe disease: a case series and literature review. Mol Genet Metab 106(3):301\u2013309","journal-title":"Mol Genet Metab"},{"key":"8219_CR28","first-page":"527","volume":"21","author":"M Restel","year":"2014","unstructured":"Restel M, Bochynska A, Chahwan M et al (2014) Encymatic replacement therapy in patients with late-onset Pompe\u2019s disease\u2014a 5-year follow up. Eur J Neurol 21:527","journal-title":"Eur J Neurol"},{"issue":"1","key":"8219_CR29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","volume":"257","author":"S Strothotte","year":"2010","unstructured":"Strothotte S, Strigl-Pill N, Grunert B et al (2010) Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial. J Neurol 257(1):91\u201397","journal-title":"J Neurol"},{"issue":"12","key":"8219_CR30","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.nmd.2010.07.277","volume":"20","author":"CI Capelle van","year":"2010","unstructured":"van Capelle CI, van der Beek NA, Hagemans ML et al (2010) Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study. Neuromuscul Disord 20(12):775\u2013782","journal-title":"Neuromuscul Disord"},{"issue":"6","key":"8219_CR31","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2008.04.009","volume":"18","author":"CI Capelle van","year":"2008","unstructured":"van Capelle CI, Winkel LP, Hagemans ML et al (2008) Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease. Neuromuscul Disord 18(6):447\u2013452","journal-title":"Neuromuscul Disord"},{"issue":"SUPPL C","key":"8219_CR32","doi-asserted-by":"crossref","first-page":"S86","DOI":"10.1016\/S0149-2918(07)80460-7","volume":"29","author":"R Hartung","year":"2007","unstructured":"Hartung R, Chamsi-Bacha F, Beck M, Mengel E (2007) Initial therapy response of 6 months of enzyme replacement therapy in 11 Juvenile\/Adult M. Pompe patients. Clin Ther 29(Suppl C):S86\u2013S87","journal-title":"Clin Ther"},{"issue":"1\u20132","key":"8219_CR33","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s10354-012-0153-5","volume":"163","author":"I Schneider","year":"2013","unstructured":"Schneider I, Hanisch F, Muller T, Schmidt B, Zierz S (2013) Respiratory function in late-onset Pompe disease patients receiving long-term enzyme replacement therapy for more than 48 months. Wien Med Wochenschr 163(1\u20132):40\u201344","journal-title":"Wien Med Wochenschr"},{"issue":"5","key":"8219_CR34","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","volume":"35","author":"C Regnery","year":"2012","unstructured":"Regnery C, Kornblum C, Hanisch F et al (2012) 36\u00a0months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy. J Inherit Metab Dis 35(5):837\u2013845","journal-title":"J Inherit Metab Dis"},{"issue":"3","key":"8219_CR35","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1756285609103324","volume":"2","author":"C Angelini","year":"2009","unstructured":"Angelini C, Semplicini C, Tonin P et al (2009) Progress in enzyme replacement therapy in glycogen storage disease type II. Ther Adv Neurol Disord 2(3):143\u2013153","journal-title":"Ther Adv Neurol Disord"},{"issue":"5","key":"8219_CR36","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00408-013-9489-x","volume":"191","author":"A Vianello","year":"2013","unstructured":"Vianello A, Semplicini C, Paladini L et al (2013) Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency. Lung 191(5):537\u2013544","journal-title":"Lung"},{"issue":"7","key":"8219_CR37","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/j.1468-1331.2010.02959.x","volume":"17","author":"S Ravaglia","year":"2010","unstructured":"Ravaglia S, Danesino C, Moglia A et al (2010) Changes in nutritional status and body composition during enzyme replacement therapy in adult-onset type II glycogenosis. Eur J Neurol 17(7):957\u2013962","journal-title":"Eur J Neurol"},{"issue":"5","key":"8219_CR38","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","volume":"259","author":"C Angelini","year":"2012","unstructured":"Angelini C, Semplicini C, Ravaglia S et al (2012) Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years. J Neurol 259(5):952\u2013958","journal-title":"J Neurol"},{"issue":"4","key":"8219_CR39","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1212\/01.wnl.0000198776.53007.2c","volume":"66","author":"MLC Hagemans","year":"2006","unstructured":"Hagemans MLC, Hop WJC, Van Doom PA, Reuser AJJ, Van Der Ploeg AT (2006) Course of disability and respiratory function in untreated late-onset Pompe disease. Neurology 66(4):581\u2013583","journal-title":"Neurology"},{"key":"8219_CR40","unstructured":"Gungor D, De Vries J, Brusse E et al. (2013) Enzyme replacement therapy and fatigue in adults with Pompe disease. BMC Musculoskelet Disord 109(2):174\u2013178"},{"key":"8219_CR41","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/1750-1172-8-160","volume":"8","author":"R Lachmann","year":"2013","unstructured":"Lachmann R, Schoser B (2013) The clinical relevance of outcomes used in late-onset Pompe disease: can we do better? Orphanet J Rare Dis 8:160","journal-title":"Orphanet J Rare Dis"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8219-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00415-016-8219-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-016-8219-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T13:40:26Z","timestamp":1498311626000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00415-016-8219-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,2]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017,4]]}},"alternative-id":["8219"],"URL":"https:\/\/doi.org\/10.1007\/s00415-016-8219-8","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,2]]}}}